Nektar Therapeutics (NKTR)
| Market Cap | 1.41B +30.7% |
| Revenue (ttm) | 54.59M -27.2% |
| Net Income | -157.13M |
| EPS | -6.47 |
| Shares Out | 34.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,174,737 |
| Open | 40.38 |
| Previous Close | 40.80 |
| Day's Range | 40.33 - 42.38 |
| 52-Week Range | 33.40 - 109.00 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 133.36 (+223.93%) |
| Est. Earnings | Nov 5, 2026 |
About NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col... [Read more]
Financial Performance
In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price target is $133.36, which is an increase of 223.93% from the latest price.
News
3 ‘Strong Buy’ High-Risk/High-Reward Stocks to Bank on for 100%+ Upside Potential
Nektar Therapeutics ($NKTR), Applied Aerospace & Defense ($AADX), and T1 Energy ($TE) are three high-risk, high-reward stocks backed by Wall Street. They are all currently rated a Strong Buy and…
Nektar initiated with a Market Perform at Raymond James
Raymond James initiated coverage of Nektar (NKTR) with a Market Perform rating and no price target Treg modulation is “a scientifically compelling approach in autoimmune disease” and rezpegaldesleukin...
Nektar 60% selloff brings ‘attractive buying opportunity,’ says Citi
Citi views the 60% selloff in shares of Nektar (NKTR) since the April highs as an “attractive buying opportunity.” There has been no negative news that impacts rezpegaldesleukin’s clinical or…
Nektar selloff yesterday overdone, says H.C. Wainwright
H.C. Wainwright analyst Arthur He views the 22% pullback yesterday in shares of Nektar (NKTR) as overdone. The company presented 52-week treatment and six-month off-treatment data from the Phase 2b…
Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies
Jefferies analyst Roger Song sees the selloff in shares of Nektar (NKTR) following updated rezpegaldesleukin data “unwarranted.” The off-treatment data “does not change our thesis,” says the analyst, ...
William Blair says rezpeg data a positive for Nektar
William Blair analyst Andy Hsieh maintained an Outperform rating on Nektar (NKTR) Therapeutics following updated rezpegaldesleukin, or rezpeg, datathat the firm believes “adds to the growing body of e...
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.
Nektar Therapeutics Transcript: Study update
REZPEG demonstrated robust, durable efficacy and a favorable safety profile in severe alopecia areata, with 63% of responders maintaining hair regrowth six months after stopping treatment. Biomarker data in atopic dermatitis confirmed rapid, broad immune modulation, supporting REZPEG’s differentiated mechanism and potential as a first-line therapy.
Nektar Therapeutics Slides: Study update
Nektar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Nektar Therapeutics Press release: Study update
Nektar Therapeutics issued a press release on October 1, 2026, disclosing material business information to investors.
Nektar’s rezpegaldesleukin shows efficacy in alopecia and atopic dermatitis
Nektar (NKTR) Therapeutics announced long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies presented at the European Academy of Dermatology and Venereology C...
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechan...
Nektar: Rezpegaldesleukin-associated improvements detected as early as Week 2
Nektar (NKTR) Therapeutics and collaborators at the Icahn School of Medicine at Mount Sinai announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further evidence that ...
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- ...
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata Company to host conference call with investors ...
Nektar awarded $90M in Eli Lilly breach of contract case
Nektar (NKTR) in 2023 filed a complaint in the U.S. District Court for the Northern District of California against Eli Lilly (LLY) alleging, among other claims, breach of contract and…
Nektar selloff on trial brings ‘strong entry point,’ says BTIG
BTIG says that while the $90M jury award is below the $1B initial amount Nektar (NKTR) appeared to expect in the Eli Lilly (LLY) case, completion of the litigation should…
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...
Nektar shares pressured by jury notes in Lilly case, says B. Riley
B. Riley analyst Mayank Mamtani says jury deliberations are headed to the fourth day today in Nektar’s (NKTR) breach of contract trial against Eli Lilly (LLY). The jury’s notes review…
Nektar price target lowered to $50 from $80 at Wedbush
Wedbush lowered the firm’s price target on Nektar (NKTR) to $50 from $80 and keeps a Neutral rating on the shares. Following “speculation on failed litigation” against Eli Lilly (LLY),…
Nektar dropped as jury deliberates suit against Eli Lilly
Nektar (NKTR) shares dropped yesterday as a federal jury in San Francisco continued to deliberate the company’s breach of contract lawsuit against Eli Lilly (LLY) regarding Rezpeg. Nektar claims Lilly...
Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial
Nektar (NKTR) announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegal...
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support ...